Absolute bioavailability of imidafenacin after oral administration to healthy subjects.

Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Abstract Text:

Tomoya Ohno,Susumu Nakade,Kazuki Nakayama,Junsaku Kitagawa,Shinya Ueda,Hiroyuki Miyabe,Yuichi Masuda,Yasuyuki Miyata,Tomoya Ohno,Susumu Nakade,Kazuki Nakayama,Junsaku Kitagawa,Shinya Ueda,Hiroyuki Miyabe,Yuichi Masuda,Yasuyuki Miyata,

What is already known about this subject * The absolute bioavailability of imidafenacin in rats and dogs is 5.6% and 36.1%, respectively. * The pharmacokinetic profiles of imidafenacin after oral administration have been revealed. * Imidafenacin is primarily metabolized to metabolites by CYP3A4 and UGT1A4. What this study adds * The absolute bioavailability of imidafenacin in human is 57.8%. * The pharmacokinetic profiles of imidafenacin after intravenous administration are revealed. * The formation of metabolites in the plasma is caused mainly by first-pass effects. Aims To investigate the absolute bioavailability of imidafenacin, a new muscarinic receptor antagonist, a single oral dose of 0.1 mg imidafenacin was compared with an intravenous (i.v.) infusion dose of 0.028 mg of the drug in healthy subjects. Methods Fourteen healthy male subjects, aged 21-45 years, received a single oral dose of 0.1 mg imidafenacin or an i.v. infusion dose of 0.028 mg imidafenacin over 15 min at two treatment sessions separated by a 1-week wash-out period. Plasma concentrations of imidafenacin and the major metabolites M-2 and imidafenacin-N-glucuronide (N-Glu) were determined. The urinary excretion of imidafenacin was also evaluated. Analytes in biological samples were measured by liquid chromatography tandem mass spectrometry. Results The absolute oral bioavailability of imidafenacin was 57.8% (95% confidence interval 54.1, 61.4) with a total clearance of 29.5 +/- 6.3 l h(-1). The steady-state volume of distribution was 122 +/- 28 l, suggesting that imidafenacin distributes to tissues. Renal clearance after i.v. infusion was 3.44 +/- 1.08 l h(-1), demonstrating that renal clearance plays only a minor role in the elimination of imidafenacin. The ratio of AUC(t) of both M-2 and N-Glu to that of imidafenacin was reduced after i.v. infusion from that seen after oral administration, suggesting that M-2 and N-Glu in plasma after oral administration were generated primarily due to first-pass metabolism. No serious adverse events were reported during the study. Conclusions The absolute mean oral bioavailability of imidafenacin was determined to be 57.8%. Imidafenacin was well tolerated following both oral administration and i.v. infusion.

Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Publishing Authors By Initials

T Ohno,S Nakade,K Nakayama,J Kitagawa,S Ueda,H Miyabe,Y Masuda,Y Miyata,T Ohno,S Nakade,K Nakayama,J Kitagawa,S Ueda,H Miyabe,Y Masuda,Y Miyata,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: British journal of clinical pharmacology

VOLUME: 65

Page Numbers: 197-202

Journal Abbreviation:

ISSN: 1365-2125

DAY: 6

MONTH: Feb

YEAR: 2008

Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7503323

Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Absolute bioavailability of imidafenacin after oral administration to healthy subjects.

AFFILIATION: Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co., Ltd, Ibaraki, Japan.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Br J Clin Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Absolute bioavailability of imidafenacin after oral administration to healthy subjects Related Publications

• A large deletion of the PROS1 gene in a deep vein thrombosis patient with protein S deficiency.
• A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia.
• A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia.
• Analysis of the p450 aromatase gene expression in the Xenopus brain and gonad.
• Bone regeneration by recombinant human bone morphogenetic protein-2 and a novel biodegradable carrier in a rabbit ulnar defect model.
• Changes of gene expression by lysophosphatidylcholine in vascular endothelial cells: 12 up-regulated distinct genes including 5 cell growth-related, 3 thrombosis-related, and 4 others.
• Cytoskeletal "jellyfish" structure of Mycoplasma mobile.
• Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
• Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells.
• Distinct properties of corticothalamic and primary sensory synapses to thalamic neurons.
• Editorial.
• Establishment of a sandwich ELISA for human megsin, a kidney-specific serine protease inhibitor.
• Identification of a cross-linked peptide of a covalent complex between adrenodoxin reductase and adrenodoxin.
• Insecticide susceptibility of surviving Cotesia plutellae (Hym: Braconidae) and Diaeretiella rapae (M'Intosh) (Hym: Aphidiidae) as affected by sublethal insecticide dosages on host insects.
• Interleukin-11 acts synergistically with bone morphogenetic protein-2 to accelerate bone formation in a rat ectopic model.
• Interleukin-11 induces osteoblast differentiation and acts synergistically with bone morphogenetic protein-2 in C3H10T1/2 cells.
• Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods.
• New series of antiprion compounds: pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation.
• Outbreak of CTX-M-3-type extended-spectrum beta-lactamase-producing Enterobacter cloacae in a pediatric ward.
• Preliminary X-ray studies on Serratia protease.
• Protein tyrosine kinase 2beta as a candidate gene for hypertension.
• Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
• Studies on denitrification. XIV. The electron donating system in the reduction of nitric oxide and nitrate.
• Survey of the morphogenetic dynamics of the ventricular surface of the developing mouse neocortex.
• Synergism between interleukin-11 and bone morphogenetic protein-2 in the healing of segmental bone defects in a rabbit model.
• The NH2-terminal structures of human and rat liver microsomal NADH-cytochrome b5 reductases.
• Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model.
• [A case of pancreatic endocrine tumor associated with Cushing's syndrome]
• [Atrioventricular dissociation]
• [Molecular mechanism of Mycoplasma gliding; a unique biomotility]